JT
Insider
James N Topper
DirectorJames N Topper (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). Across 2 priced purchase filings, the average 21-session return was +141.2% from execution and +103.9% from disclosure (delay-adjusted; derived). The largest single filing was $167K of NAMS (8,584 sh × $19.50, as filed), executed Jun 16 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+141.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+103.9%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$274K
shares × price, as filed
Last traded
Jun 16 2025
Filed Jun 18 2025
Median ADV $32.2M across their filed names
Open performance→Volume by month
Buys $274K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 24 months
Most traded names
NAMSRecent filings
NAMSPURCHASE
NewAmsterdam Pharma Company N.V.
View filing →
$167K8,584 sh × $19.50
Exec Jun 16 2025
Filed Jun 18 2025 · 5:30 PM ET PHATPURCHASE Phathom Pharmaceuticals, Inc. View filing → $106K
33,376 sh × $3.19
Exec May 9 2025
Filed May 13 2025 · 5:30 PM ET